Skip to main content
. 2019 Jun 14;9:30. doi: 10.1186/s13601-019-0269-4

Table 2.

Baseline clinical characteristics in patients, who were followed for 12 year (N = 38), with primary or revision ESS at baseline

Primary ESS Revision ESS P value
N = 19 N = 19
Baseline clinical characteristics (N = 38)
Clinical characteristics
 Men/women, N/N (%/%) 13/6 (68/32) 12/7 (63/37) 1.00
 Age (y), median (IQR) 44 (31–54) 47 (37–53) 0.863
 Comorbidity
  Allergic sensitizaion, N (%) 10 (53) 10 (53) 1.00
  Asthma, N (%) 5 (26) 10 (53) 0.184
  AERD, N (%) 3 (16) 7 (37) 0.269
 Total NP score, median (IQR) 4 (3–5) 4 (4–6) 0.644
 Total symptom score, median (IQR) 8 (7–12) 9 (8–12) 0.443
Tissue biomarkers, median (IQR)
 IL-5 (pg/ml) 86.02 (43.00–237.87) 228.14 (133.24–484.44) <0.05
 Detectable IL-5, N (%) 10 (53) 16 (84) 0.079
 IL-5Rα (pg/ml) 2704.74 (1116.04–13,162.88) 15,383.50 (4036.26–28,350.59) <0.05
 TGF-β1 (pg/ml) 8934.18 (7356.03–15,825.42) 12,769.26 (7562.52–27,256.90) 0.477
 MPO (ng/ml) 5251.91 (2634.00–11,020.06) 9255.17 (4602.93–19,868.30) 0.061
 IL-18 (pg/ml) 14,982.30 (7761.63–25,611.80) 15,051.30 (4698.93–19,633.68) 0.354
 ECP (mg/l) 5.71 (0.86–12.93) 13.48 (4.75–28.46) <0.05
 Total IgE (kU/l) 322.95 (146.30–1348.16) 432.30 (251.83–1156.39) 0.639
 Detectable IgE to SAE, N (%) 8 (42) 8 (42) 1.00
Nasal secretion biomarkers, median (IQR)
 IL-5 (pg/ml) 30.00 (30.00–109.22) 94.81 (30.00–169.86) 0.285
 IL-5Rα (pg/ml) 667.55 (439.40–791.74) 2897.67 (562.93–10,030.07) 0.076
 ECP (mg/l) 0.36 (0.12–0.79) 0.54 (0.32–3.57) 0.100
 IgE (kU/l) 174.15 (40.49–312.94) 324.35 (100.14–662.78) 0.394
Serum biomarkers, median (IQR)
 IL-5 (pg/ml) BDL BDL ND
 IL-5Ra (pg/ml) 334.60 (235.60–710.05) 414.90 (364.30–866.60) 0.471
 ECP (µg/l) 26.10 (21.60–45.15) 23.90 (19.75–189.50) 0.601
 IgE (kU/l) 217.00 (51.15–715.00) 50.20 (29.35–189.50) 0.110

Italic values indicate significance of P value (P < 0.05)

N number, IQR interquartile range, BDL below detection level, ND not done